Loading
A phase 2/3 trial of Cisplatin, Bevacizumab, Carboplatin in cervical cancer, run by Bio-Thera Solutions, now recruiting.
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer is a phase 2/3 interventional study registered as NCT06123884 by Bio-Thera Solutions, with 526 participants planned, started 2023-12-13 and due to reach its primary completion in 2026-09. Interventions recorded: Recombinant humanized anti-PD-1 monoclonal antibody injection, Cisplatin, Bevacizumab Injection, carboplatin, Paclitaxel for Injection. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Anti-angiogenic therapy, Paclitaxel / nab-paclitaxel.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Cervical cancer, Cisplatin.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Anti-angiogenic therapy, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Cervical cancer, Cisplatin.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.